← 產業報告目錄
Viral and Non-Viral Vector Manufacturing Market Size, Share & Trends Analysis Report By Vector type (Viral Vector, Non-Viral Vector), By Disease (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases), By Application, By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-26頁數 170報告編號 INSIGHTACE-3cd83e678e
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Viral and Non-Viral Vector Manufacturing Market on a global scale was estimated at USD 8.0 Billion in 2024 and is set to attain USD 56.8 Billion by 2034, with a projected CAGR of 21.9% between 2025 and 2034.
Viral and Non-Viral Vector Manufacturing encompasses genetically modified viruses utilised as carriers for introducing exogenous genetic material into cells through their viral genome. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Viral and Non-Viral Vector Manufacturing Market Snapshot
Chapter 4. Global Viral and Non-Viral Vector Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Vector Types Estimates & Trend Analysis
5.1. By Vector Types & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Vector Types:
5.2.1. Viral Vector
5.2.1.1. Adenoviral Vector
5.2.1.2. Retroviral Vector
5.2.1.3. Adeno-Associated Viral Vector
5.2.1.4. Lentiviral Vector
5.2.1.5. Vaccinia Viral Vector
5.2.1.6. Other Viral Vector
5.2.2. Non-Viral Vectors
5.2.2.1. Plasmid DNA
5.2.2.2. Lipid-Based Non-Viral Vector
5.2.2.3. Polymer-Based Non-Viral Vector
5.2.2.4. Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)
Chapter 6. Market Segmentation 2: By Diseases Estimates & Trend Analysis
6.1. By Diseases & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Diseases:
6.2.1. Cancer
6.2.2. Genetic Disease
6.2.3. Infectious Disease
6.2.4. Cardiovascular Disease
6.2.5. Other Diseases
Chapter 7. Market Segmentation 3: By Applications Estimates & Trend Analysis
7.1. By Applications & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Applications:
7.2.1. Gene Therapy
7.2.1.1. Viral Vector
7.2.1.2. Non-Viral Vector
7.2.2. Vaccinology
7.2.2.1. Viral Vector
7.2.2.2. Non-Viral Vector
7.2.3. Cell Therapy
7.2.3.1. Viral Vector
7.2.3.2. Non-Viral Vector
7.2.4. Other Applications
7.2.4.1. Viral Vector
7.2.4.2. Non-Viral Vector
Chapter 8. Viral and Non-Viral Vector Manufacturing Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts By Vector Types, 2021-2034
8.1.2. North America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts By Diseases, 2021-2034
8.1.3. North America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by Applications, 2021-2034
8.1.4. North America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Vector Types, 2021-2034
8.2.2. Europe Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Diseases, 2021-2034
8.2.3. Europe Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by Applications, 2021-2034
8.2.4. Europe Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Vector Types, 2021-2034
8.3.2. Asia Pacific Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Diseases, 2021-2034
8.3.3. Asia Pacific Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by Applications, 2021-2034
8.3.4. Asia Pacific Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Vector Types, 2021-2034
8.4.2. Latin America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Diseases, 2021-2034
8.4.3. Latin America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by Applications, 2021-2034
8.4.4. Latin America Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Vector Types, 2021-2034
8.5.2. Middle East & Africa Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) By Diseases, 2021-2034
8.5.3. Middle East & Africa Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) estimates and forecasts by Applications, 2021-2034
8.5.4. Middle East & Africa Viral and Non-Viral Vector Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Boehringer Ingelheim
9.2.2. Catalent, Inc.
9.2.3. FUJIFILM Holdings Corporation
9.2.4. Danaher Corporation
9.2.5. Genscript Biotech Corporation
9.2.6. Lonza Group AG
9.2.7. Merck KGaA Inc.
9.2.8. Oxford Biomedica plc
9.2.9. Sartorius AG
9.2.10. Takara Bio Inc.
9.2.11. Thermo Fisher Scientific Inc.
9.2.12. Wuxi AppTec
9.2.13. Acuitas Therapeutics
9.2.14. Evonik Industries AG
9.2.15. Exelead, Inc.
9.2.16. Entos Pharmaceuticals
9.2.17. Genevant Sciences GmbH
9.2.18. T&T Scientific Corporation
9.2.19. Moderna, Inc.
9.2.20. CureVac N.V.
9.2.21. Cognate BioServices Inc. (Cobra Biologics)
9.2.22. Genezen Laboratories
9.2.23. Yposkesi
9.2.24. Waisman Biomanufacturing
9.2.25. Advanced Bioscience Laboratories, Inc. (Abl Inc.)
9.2.26. Novasep Holding S.A.S.
9.2.27. Batavia Biosciences B.V.
9.2.28. Biovion Oy
9.2.29. Sirion Biotech Gmbh.
9.2.30. Virovek Incorporation
9.2.31. Biontech Imfs Gmbh
9.2.32. Vivebiotech S.L.
9.2.33. Creative Biogene
9.2.34. Uniqure NV
9.2.35. Cell and Gene Therapy Catapult
9.2.36. Cevec. Pharmaceuticals Gmbh
9.2.37. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們